Alex S. V.
- Country
- Spain
- Department
- Infectious Disease Department
Research Overview
- Staphylococcus aureus Bacteraemia Network Adaptive Platform Trial (SNAP)
- Phase 3 Randomized Study of Echinocandin Followed by Ibrexafungerp vs. Echinocandin Followed by Fluconazole in Invasive Candidiasis/Candidemia
- Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of VE303 for Recurrent Clostridioides difficile Infection Prevention in Adults
Data & Insights
Has run more than one trial at 16 of 98 partner sites.
Specializations
Fungal Infections
The investigator specializes in research targeting complex invasive fungal infections, with particular emphasis on candidemia and invasive candidiasis. Their work explores innovative treatment approaches using echinocandins and novel antifungal agents.
- Systemic Candida Infections
- Antifungal Therapeutic Strategies
- Oral Antifungal Treatments
Focus includes evaluation of sequential therapy transitions from intravenous to oral antifungal medications.
Pulmonary Mycology
Expertise extends to the treatment of refractory invasive pulmonary aspergillosis, investigating novel therapeutic combinations including nebulized treatments alongside systemic antifungal therapies.
- Resistant Fungal Infections
- Combination Antifungal Approaches
- Inhaled Antifungal Treatments
Special interest in developing solutions for treatment-resistant pulmonary fungal infections.
Gastrointestinal Infections
The investigator conducts research in the prevention and treatment of Clostridioides difficile infection, focusing on innovative therapeutic approaches to prevent disease recurrence.
- Recurrent C. difficile Prevention
- Novel Therapeutic Agents
- Infection Control Strategies
Emphasis on developing preventive interventions for recurring infections.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.